Free Trial

Demant A/S (WILYY) Stock Forecast & Price Target

Demant A/S logo
$18.87 0.00 (0.00%)
(As of 11/20/2024 ET)

Demant A/S - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
2

Based on 3 Wall Street analysts who have issued ratings for Demant A/S in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 1 has given a hold rating, and 2 have given a strong buy rating for WILYY.

Consensus Price Target

N/A

Get the Latest News and Ratings for WILYY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Demant A/S and its competitors.

Sign Up

WILYY Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
N/A
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
N/A
4 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
N/A
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
N/A
0 Sell rating(s)
Consensus Price TargetN/AN/AN/AN/A
Forecasted UpsideN/AN/AN/AN/A
Consensus Rating
Buy
Buy
N/A
Moderate Buy

WILYY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

WILYY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Demant A/S Stock vs. The Competition

TypeDemant A/SMedical CompaniesS&P 500
Consensus Rating Score
3.33
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted UpsideN/A26,931.54% Upside9.83% Upside
News Sentiment Rating
Neutral News

See Recent WILYY News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/21/2024The Goldman Sachs Group
2 of 5 stars
R. Felton
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
9/13/2024Hsbc Global Res
0 of 5 stars
R. Department
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
8/28/2024UBS Group
4 of 5 stars
G. Doyle
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
8/21/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Overweight
8/8/2023Nordea Equity Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
5/12/2023Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
5/8/2023Handelsbanken
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
3/28/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Equal Weight
2/8/2023Danske
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
1/25/2023BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Neutral
1/25/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
11/22/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target170.00 ➝ 180.00

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 10:38 AM ET.


WILYY Forecast - Frequently Asked Questions

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Demant A/S in the last year. There is currently 1 hold rating and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" WILYY shares.

According to analysts, Demant A/S's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.

Over the previous 90 days, Demant A/S's stock had 3 upgrades by analysts.

Demant A/S has been rated by research analysts at Hsbc Global Res, The Goldman Sachs Group, and UBS Group in the past 90 days.

Analysts like Demant A/S more than other "medical" companies. The consensus rating for Demant A/S is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how WILYY compares to other companies.


This page (OTCMKTS:WILYY) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners